Psychedelic Drugs Market
Psychedelic Drugs Market: Industry Trends and Global Forecasts, till 2035: Distribution by Origin of Substance (Natural and Synthetic), Type of Psychedelic Substance (Gamma-hydroxybutyrate, Ketamine, MDMA, and Psilocybin), Target Disease Indication (Depression and Anxiety Disorders, Pain Disorders, Sleep Related Disorders and Trauma), Route of Administration (Oral, Intravenous, Intranasal and Sublingual) and Geographical Regions (North America, Europe, Asia Pacific and Rest of the World)
-
Lowest Price Guaranteed
-
Pages
280 -
Last Updated
September 2026 -
View Count
22033 -
What is the Global Psychedelic Drugs Market Size?
The psychedelic drugs market is estimated to grow from USD 2.77 billion in 2024 to reach USD 3.19 billion in 2025 and USD 12.89 billion by 2035, representing a higher CAGR of 15% during the forecast period.
 |
To learn more about this report, request a free sample copy
Mental health disorders, including those linked to psychedelic use, cause over USD 1 trillion in annual global productivity losses. During the COVID-19 lockdown, the prescriptions for antidepressants, anti-anxiety drugs and digital psychotherapeutics in the US rose by ~20%, highlighting the growing prevalence of psychiatric conditions and the urgent need for effective treatments.
 |
 |
 |
According to the World Health Organization, several critical barriers hinder effective treatment of depression and related mental illnesses. These include lack of understanding of such conditions, persistent social stigma, frequent misdiagnoses, and a notable scarcity of effective medications. Therefore, innovative approaches are essential to overcome stigma, enhance diagnostic accuracy, and provide novel therapeutic solutions. The treatment-development landscape for depressive disorders provides context for evaluating investigational psychedelic approaches alongside other pharmacological strategies.
 |
 |
 |
Emerging clinical evidence highlights psychedelic substances' therapeutic potential for psychiatric conditions like depression when given in controlled doses. Experts are optimistic about their ability to treat chronic mental health disorders and acute psychological impacts from events like COVID-19. As the evidence base continues to expand, psychedelics are increasingly being viewed not as recreational drugs, but as powerful tools with the potential to transform mental health care.
 |
 |
 |
Psychedelic Drugs Market: Report Attributes
| Key Report Attributes | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2035 | |
| Market Size 2025 | $ 3.19 Billion | |
| Market Size 2035 | $ 12.89 Billion | |
| CAGR (Till 2035) | 15% | |
The psychedelic drugs market analysis also features the likely distribution of the current and forecasted opportunity within this domain across various segments, such as origin of substance, type of psychedelic substance, target disease indication, route of administration, and geographical regions.
We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.
What are the Recent Developments in the Psychedelic Drugs Market ?
Several recent developments in the field of psychedelic drugs have occurred, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall market trends detailed in our analysis.
- In October 2025, AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' bretisilocin program, a next-generation psychedelic compound in Phase II development for major depressive disorder, expanding AbbVie's psychiatry pipeline with an investigational short-acting psychedelic therapy.
- In August 2025, AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' bretisilocin program, a novel investigational psychedelic therapy for major depressive disorder, for up to USD 1.2.
- In June 2025, Atai Life Sciences announced a merger with Beckley Psytech in an all stock deal valued at USD 370 million, assigning Beckley a USD 370 million valuation and forming the combined company AtaiBeckley. The new entity will focus on advancing Beckley’s psychedelic pipeline, including a 5-MeO-DMT candidate originally derived from smoking toad secretions, for the treatment of mental health disorders.
- In April 2025, MindMed announced that the first patient had been dosed in its Phase III Emerge study of MM120 ODT, a proprietary orally disintegrating tablet formulation of lysergide D-tartrate being evaluated for major depressive disorder, building on positive Phase 2b results in generalized anxiety disorder that showed rapid and sustained anxiolytic and antidepressant like effects.
Psychedelic Drugs Market Segmentation Insights
The market research report presents an in-depth analysis of the various psychedelic drugs developers, across different segments, as defined in the table below:
Psychedelic Drugs Market: Market Segmentations
| Market Segmentations | Details | |
| Origin of Substance |
|
|
| Type of Psychdelic Substance |
|
|
| Target Disease Indication |
|
|
| Route of Administration |
|
|
| Geographical Regions |
|
|
Industry Experts on Psychedelic Drugs Market
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
- Founder & Chief Executive Officer, Small Company
- Chief Operating Officer and Chief Medical Officer, Mid-sized Company
- Chief Operating Officer, Small Company
- Chief Communications Officer, Mid-sized Company
- Associate Research Scientist, Large Company
Psychedelic drugs domain will mark a turning point in 2025. Manish Agrawal (MD, Cofounder and CEO, Sunstone Therapies) discussed psychedelic-assisted therapy in oncology and palliative care at the Psychedelic Science Conference 2025, highlighting innovative dyadic treatment models and challenges in measuring outcomes. In this context, he stated, “I've been speaking to more oncology groups, and certainly the interest has increased, and the openness has increased to psychedelic-assisted therapy in general, because of the publications that have been coming out and increased public awareness, and that has trickled down to oncologists and the oncology world.”
How is the Psychedelic Drugs Market Segmented?
Market Share by Type of Psychedelic Substance: Ketamine is Psychedelic Market Holds the Largest Share
- The segment highlights the distribution of the overall market across various types of psychedelic substances namely, Gamma-hydroxybutyrate, Ketamine, MDMA, and Psilocybin. According to our projections, the Ketamine segment is likely to capture majority of the overall market share in 2025, and this trend is unlikely to change in the future.
- It is worth highlighting that the market for Psilocybin is likely to grow at a relatively higher CAGR, during the forecast period. This is a result of the increasing adoption of such psychedelic-assisted therapies owing to their therapeutic potential in the treatment of addiction and mental health disorders.
Market Share by Geographical Regions : North America is Likely to Capture Majority of the Psychedelic Drugs Market in the Coming Years
- This segment highlights the distribution of market for psychedelic drugs market across various geographical regions, such as North America, Europe, Asia-Pacific, and rest of the world. According to our projections, North America is likely to capture the majority of the overall market share in 2025.
- This trend is likely to be the result of various factors, such as high prevalence of mental health disorders, supportive regulatory guidelines, strong healthcare infrastructure and legal status of psilocybin therapy in North America.
Psychedelic Drugs Market: Report Deliverables
| Report Deliverables | Details | |
| Analytical Insights Covered |
|
|
| Strategic Insights Covered | Executive Infographic Summary | |
| Key Psychedelic Drugs Developing Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
What are the Major Takeaways of Psychedelic Drugs Market?
The “Psychedelic Drugs Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, clinical trial analysis, clinical trial site analysis, KOL analysis, academic grants analysis, partnership and collaboration analysis, mergers and acquisitions analysis, and market size and future opportunities within the psychedelic drugs industry, during the forecast period.
How is the Competitive Landscape of Psychedelic Drugs Developers Fragmented?
The current market landscape features over 70 companies in the development of psychedelic therapies. Notably, majority of the firms engaged in this domain (71%) are based in North America, followed by those headquartered in Europe (23%) and Asia Pacific (6%).
What is the Opportunity for the Psychedelic Drugs Market?
The global market size is likely to be worth $ 3.19 billion in 2025 and will reach $ 12.89 billion by 2035. In terms of therapeutic indications, the treatment for post-traumatic stress disorder is likely to capture majority of the market share.
This trend is ascribed to the increasing clinical evidence supporting the efficacy of psychedelics like MDMA and psilocybin in treating PTSD, coupled with growing regulatory approvals and heightened investment in research for psychedelic-assisted therapies.
What are the Key Drivers of Psychedelic Drugs Market?
The global psychedelic drugs market is growing due to strong clinical evidence, supportive regulatory changes, and increased investments. Additionally, the rising mental health disorders and shifting public attitudes are further driving this expansion.
What are the Key Opportunities in Psychedelic Drugs Market?
The global market is poised for substantial growth owing to its therapeutic potential, evolving regulatory landscapes, innovative drug development, and increasing acceptance. Stakeholders can leverage these opportunities by investing in research, navigating regulatory changes, and targeting emerging markets, particularly in mental health applications.
What are the Key Challenges in Psychedelic Drugs Market?
The market faces significant challenges related to regulatory barriers, safety concerns, social stigma, and clinical complexities. Overcoming these hurdles will require coordinated efforts in policy reform, public education, robust clinical research, and investment in infrastructure.
From the Author’s Desk
Author’s View on Psychedelic Market
The psychedelic drugs market has gained significant momentum in recent years, driven by the therapeutic potential of substances, such as psilocybin, MDMA, and ketamine. These compounds are being investigated for their potential to treat mental health disorders, including depression, PTSD, and anxiety. One of the key advancements in the market is the growing recognition of the benefits of psychedelic-assisted therapy, which has shown promise in clinical trial services.
About Authors
Lead Author: Nancy Kapila
Lead Reviewer: Parneet Kaur
Chief Editor: Prachi Bhalla
Glossary
- Psychedelic Drugs: Psychedelic drugs are a class of psychoactive substances that primarily induce altered states of consciousness, characterized by changes in perception, mood, and thought
- Psychedelic Disorders: Psychedelic disorders, as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), refer to conditions that arise after the use of psychedelic drugs.
- Trauma: Trauma is the lasting emotional response that stems from a distressing or disturbing event that overwhelms an individual's ability to cope.
- Depression: Depression, also known as major depressive disorder or clinical depression, is a mood disorder characterized by a persistent feeling of sadness and loss of interest in activities that were once enjoyable.
- PTSD: Post-traumatic stress disorder (PTSD) is a mental health condition that can develop after experiencing or witnessing a traumatic event.